RxSight, Inc. 8-K

What Happened

• RxSight (RXST) filed an 8-K (furnished) on Jan 12, 2026 disclosing a press release dated Jan 11, 2026 that announced certain preliminary, unaudited fourth-quarter and full-year 2025 financial and operational results. The press release is furnished as Exhibit 99.1.
• The company also announced the appointment of Mark Wilterding as Chief Financial Officer, effective Jan 11, 2026. Mr. Wilterding was appointed Dec 13, 2025 and joined from Edwards Lifesciences. He will replace Shelley Thunen as principal financial and accounting officer.

Key Details

• Press release: preliminary unaudited Q4 and full-year 2025 results (Exhibit 99.1); information furnished (not “filed”) under Form 8-K General Instruction B.2.
• CFO hire: Mark Wilterding (age 48) effective Jan 11, 2026; prior roles include senior VP, global finance and investor relations at Edwards Lifesciences and director, investor relations at Medtronic.
• Compensation and equity: annual base salary $550,000; annual bonus eligible up to 65% of base salary; sign‑on bonus amount to be determined. New‑hire equity: option to purchase 258,770 shares and 163,528 RSUs.
• Vesting and exercise terms: option exercise price = Nasdaq closing price on grant date (Jan 12, 2026); option vests 25% after 1 year, then monthly over 3 years (4‑year schedule). RSUs vest 1/8 on Feb 28, 2026, then 1/8 every six months (over four years). Mr. Wilterding entered standard proprietary information and change‑in‑control severance agreements and an indemnification agreement.

Why It Matters

• The furnished press release signals RxSight will provide preliminary revenue/operational metrics for Q4 and FY2025; investors should review Exhibit 99.1 for the specific figures and await audited or final periodic filings for confirmation.
• The CFO change is material for financial leadership and investor communications. Mr. Wilterding’s compensation and meaningful equity grants align his incentives with shareholder performance; vesting schedules and severance terms are disclosed and consistent with company practice.